Novartis(NVS) - 2024 Q1 - Earnings Call Presentation

Financial Performance - Novartis' Q1 2024 net sales reached $11829 million, an increase of 11% in constant currencies (cc) compared to Q1 2023 [9, 112] - Core operating income for Q1 2024 was $4537 million, a 22% increase in constant currencies compared to $3906 million in Q1 2023 [5, 112] - The core margin improved to 384%, a 340 bps increase from 384% in Q1 2023 [5] Key Growth Drivers - Entresto® demonstrated strong double-digit growth, with an increase of 36% in Q1 [206] - Kesimpta® showed significant growth of 66%, driven by strong momentum in the US and increasing penetration outside the US [194] - Cosentyx® grew by 25% in Q1, fueled by demand in core indications and strong launches [16] - Kisqali® experienced a 54% growth in metastatic breast cancer (mBC), with a leading share of new patient starts [39] - Pluvicto® demonstrated strong growth of 47% in Q1, driven by new patient starts in the US [22] - Scemblix® grew by 83% in Q1, driven by continued demand in 3L+ CML [47] Pipeline and Innovation - Iptacopan's Phase 3 APPLAUSE-IgAN study demonstrated a 38% proteinuria reduction [79] - Pluvicto® PSMAfore submission-enabling OS readout achieved in Q1, on track to file for pre-taxane indication in H2 [43] - Scemblix® 1L CML Ph3 readout was positive [8]